Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
anti-CD22 CAR-T cell therapy / Shanghai Yake Biotech
ChiCTR1800019054: Clinical study of CD19 car-t \CD22 car-t cells sequential therapy for recurrent refractory b-cell acute lymphocytic leukemia	Recruiting	N/A	20		Chimeric Antigen Receptor T-cell Immunotherapy	Qilu Hospital of Shandong University(Qingdao); Qilu Hospital of Shandong University(Qingdao), Shanghai YaKe Biotech Co.,Ltd.	acute lymphocytic leukemia